Frontlight ResearchEarly access
Enrolling by invitationNo phase
Long Term Follow-Up for RGX-111
Key facts
- Who runs it
- REGENXBIO Inc.
- Where
- Orange, United StatesSee the siteAlso in 1 other country, 1 site
- Trial code
- Status
- Enrolling by invitation
- People taking part
- 21 people, planned
- Started
- 24 Jul 2023
- Expected to end
- Sept 2027
- Type of study
- Observational
- Record updated
- 29 April 2026
Who can take part
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 3 criteriaShow less
Who can take part
- To be eligible, a participant must have previously received RGX-111 in a separate parent trial
- Participant or participant's legal guardian(s) is/(are) willing and able to provide written, signed informed consent
Who cannot take part
- None
Where in United States
Also in 1 other country, 1 site
- Children's Hospital of Orange CountyOrange, United StatesEnrolling by invitation
About the trial
What the trial wants to find out
RGX-111-5101 is a long-term follow up study that evaluates the long-term safety and efficacy of RGX-111 in participants who have received RGX-111 (a gene therapy intended to deliver a functional copy of the alpha-L-iduronidase gene (IDUA) to the central nervous system) in a separate parent study.
The group in the trial
- RGX-111 Recipients
Subjects who have received RGX-111 in a separate parent study.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Long-term Follow-up Study to Evaluate the Safety of RGX-111
- Record updated
- 29 April 2026